流感診斷市場規模、佔有率、成長分析、按產品、按測試、按最終用戶、按地區 - 行業預測，2024-2031 年

2022年全球流感診斷市場規模估值為13億美元，從2023年的14億美元成長到2031年的21億美元，預計在預測期內（2024-2031年）複合年成長率為4.9%。

醫療保健支出的增加和有效治療方法的進步正在導致世界中位數年齡的上升。世界衛生組織、疾病預防控制中心和歐洲疾病預防和控制中心等監管機構努力追蹤發病率和盛行率資料，以系統化應對健康挑戰。全球流感計畫 (GIP) 等聯合舉措旨在加強管理流感及相關流行病的技術援助和策略指南。儘管做出了這些努力，COVID-19 大流行仍嚴重影響了流感診斷市場，導致生產設施暫時關閉和供應鏈中斷。此外，COVID-19 和流感症狀的相似性需要同時進行檢測，在這些挑戰中推動了對流感診斷的需求，並最終推動了我們正在推廣的這一細分市場的成長。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特分析及影響
  • 競爭公司之間的敵對關係
  • 替代品的威脅
  • 買方議價能力
  • 新進入者的威脅
  • 供應商的議價能力

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 監管環境
• 案例研究
• 專利分析

流感診斷市場規模：依產品及複合年成長率（2024-2031）

• 市場概況
• 檢測套組和試劑
• 裝置
• 其他

流感診斷市場規模：按測試和複合年成長率（2024-2031）

• 市場概況
• 分子診斷測試
  • 聚合酵素鏈鎖反應
  • 恒溫核酸增幅試驗
  • 檢查
• 基於轉錄擴增的測試
• 恒溫環型核酸擴增的測試
• 基於核酸序列的擴增測試
• 常規診斷測試
• 流感快速診斷檢測
• 病毒培養測試
• 直接螢光抗體測試
• 血清學檢測

流感診斷市場規模：依最終用戶和複合年成長率（2024-2031）

• 市場概況
• 診斷實驗室
• 醫院和診所
• 其他

流感診斷市場規模與複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Thermo Fisher Scientific（US）
• Becton, Dickinson and Company（US）
• F. Hoffmann-La Roche AG（Switzerland）
• Hologic, Inc.（US）
• Abbott Laboratories, Inc.（US）
• DiaSorin（Italy）
• QIAGEN NV（Netherlands）
• Fujirebio Diagnostics, Inc.（Japan）
• Meridian Bioscience, Inc.（US）
• Luminex Corporation（US）
• Seegene Inc.（South Korea）
• Bio-Rad Laboratories, Inc.（US）
• Alere Inc.（US）
• GenMark Diagnostics, Inc.（US）
• Roche Diagnostics（Switzerland）
• BioMerieux SA（France）
• Cepheid（US）
• SD Biosensor（South Korea）
• Acon Laboratories, Inc.（US）
• Inverness Medical Innovations, Inc.（US）

結論和建議

Global Influenza Diagnostics Market size was valued at USD 1.3 billion in 2022 and is poised to grow from USD 1.4 billion in 2023 to USD 2.1 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031).

Rising healthcare expenditures and effective treatment advancements are contributing to a global increase in median age. Regulatory organizations such as WHO, CDC, and the European Centre for Disease Prevention and Control are diligently tracking incidence and prevalence data to systematically address health challenges. Collaborative initiatives like the Global Influenza Program (GIP) aim to enhance technical support and strategic guidance in managing influenza and related pandemics. Despite these efforts, the COVID-19 pandemic has significantly impacted the influenza diagnostics market, leading to temporary closures of manufacturing facilities and disruptions in supply chains. Furthermore, the similarities between COVID-19 and influenza symptoms necessitate concurrent testing, driving the demand for influenza diagnostics amidst these challenges, ultimately fostering growth in this market sector during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Diagnostics Market Segmental Analysis

Global Influenza Diagnostics Market is segmented by Product, Test, End User and Region. Based on Product, the market is segmented into Test kit and Reagents, Instruments, Other Products. Based on Test, the market is segmented into Molecular Diagnostic Test (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification, Tests), Transcription Mediated Amplification Based Assay, Loop Mediated Isothermal Amplification Based Assay, Nucleic Acid Sequence based Amplification Tests, Traditional Diagnostics Tests (Rapid Influenza Diagnostic Test, Viral Culture Test, Direct Fluorescent Antibody Test, Serological Tests). Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals and Clinics, Others. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Diagnostics Market

A key driver in the global Influenza Diagnostics market is the increased emphasis on research and development in this area. The escalating global incidence of influenza has intensified efforts to create accurate and rapid diagnostic methods for identifying influenza viruses. This focus on enhancing diagnostic capabilities is expected to significantly propel market growth. Furthermore, government initiatives aimed at combating influenza outbreaks, along with advancements in technology, are enhancing diagnostic efficacy. Additionally, the growing prevalence of related health issues, such as cardiovascular diseases and diabetes, will also contribute to the upward momentum of the Influenza Diagnostics market.

Restraints in the Global Influenza Diagnostics Market

The Global Influenza Diagnostics market faces several restraints, particularly the shortage of skilled technicians, which significantly hampers its growth potential. The scarcity of qualified professionals, compounded by an unstable regulatory environment regarding the approval of new diagnostic tests, poses a considerable challenge. Additionally, developing economies often struggle with inadequate healthcare infrastructure, further complicating the situation. As a result, these factors collectively hinder the market's expansion, making it more difficult to implement and utilize advanced diagnostic technologies effectively in the fight against influenza. Addressing these issues is crucial for fostering growth and improving diagnostic capabilities worldwide.

Market Trends of the Global Influenza Diagnostics Market

The global influenza diagnostics market is poised for substantial growth, driven by a notable rise in reported influenza cases worldwide. With the Centers for Disease Control and Prevention (CDC) estimating annual influenza-related fatalities in the U.S. between 12,000 and 79,000, the urgency for effective diagnostic solutions becomes ever more critical. Furthermore, heightened awareness surrounding the significance of early detection and proactive disease management is propelling demand for advanced testing technologies. As healthcare providers and patients prioritize timely intervention to mitigate influenza outbreaks, the market is expected to expand significantly during the forecast period, reflecting both public health imperatives and technological advancements in diagnostics.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies
• Patent Analysis

Influenza Diagnostics Market Size by Product & CAGR (2024-2031)

• Market Overview
• Test kit and Reagents
• Instruments
• Others

Influenza Diagnostics Market Size by Test & CAGR (2024-2031)

• Market Overview
• Molecular Diagnostic Test
  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification
  • Tests
• Transcription Mediated Amplification Based Assay
• Loop Mediated Isothermal Amplification Based Assay
• Nucleic Acid Sequence based Amplification Tests
• Traditional Diagnostics Tests
• Rapid Influenza Diagnostic Test
• Viral Culture Test
• Direct Fluorescent Antibody Test
• Serological Test

Influenza Diagnostics Market Size by End User & CAGR (2024-2031)

• Market Overview
• Diagnostic Laboratories
• Hospitals and Clinics
• Others

Influenza Diagnostics Market Size & CAGR (2024-2031)

• North America, (Product, Test, End User)
  • US
  • Canada
• Europe, (Product, Test, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Product, Test, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Product, Test, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Test, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Diagnostics, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meridian Bioscience, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luminex Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alere Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenMark Diagnostics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SD Biosensor (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inverness Medical Innovations, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation